UNIVERSITY OF BIRMINGHAM

Research at Birmingham

Dysregulation of maternal and placental vitamin D metabolism in preeclampsia

Tamblyn, Jennifer; Susarla, Radhika; Jenkinson, Carl; Jeffery, Louisa; Ohizua, O.; Chun, Rene; Chan, Shiao Y; Kilby, Mark; Hewison, Martin

Link to publication on Research at Birmingham portal

Accepted Manuscript

Dysregulation of maternal and placental vitamin D metabolism in preeclampsia

J.A. Tamblyn, R. Susarla, C. Jenkinson, L.E. Jeffery, O. Ohizua, R.F. Chun, S.Y. Chan, M.D. Kilby, M. Hewison

Please cite this article as: Tamblyn JA, Susarla R, Jenkinson C, Jeffery LE, Ohizua O, Chun RF, Chan SY, Kilby MD, Hewison M, Dysregulation of maternal and placental vitamin D metabolism in preeclampsia, *Placenta* (2017), doi: 10.1016/j.placenta.2016.12.019.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Dysregulation of maternal and placental vitamin D metabolism in preeclampsia**

2 Tamblyn JA[1,5,6], Susarla R[1], Jenkinson C[1], Jeffery LE[1], Ohizua O[2], Chun RF[3], Chan SY[1,4], Kilby

3 MD[1,5,6,7], Hewison M[1,6,7]

4

5 [1]Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, B15

6 2TT, UK

7 [2]Women, Children and Sexual Health Directorate, Walsall Hospitals NHS Trust, Walsall, WS2

8 9PS, UK

9 [3]Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, CA

10 90095, USA

11 [4]Department of Obstetrics and Gynecology, National University of Singapore, Singapore 119228

12 [5]Fetal Medicine Centre, Birmingham Women's Foundation Trust, Edgbaston, Birmingham, B15

13 2TG, UK

14 [6]Centre for Women's & Newborn Health, Birmingham Health Partners, Birmingham B15 2TH,

15 UK.

16 [7]Centre for Endocrinology Diabetes and Metabolism, Birmingham Health Partners, Birmingham

17 B15 2TH, UK

18

24 **Corresponding author:**
25 Address for correspondence:
26 Martin Hewison PhD
27 Institute of Metabolism & Systems Research
28 Level 2, IBR, Rm 225
29 The University of Birmingham
30 Birmingham
31 B15 2TT
32 UK

33
34 Email: m.hewison@bham.ac.uk
35 Tel: 44 (0)121 414 6908
36 Fax: 44(0)121 415 8712
37

Abstract

Introduction: Epidemiology has linked preeclampsia (PET) to decreased maternal serum 25-hydroxyvitamin D3 (25(OH)D3). However, alterations in systemic and placental/decidual transport and metabolism of 25(OH)D3 during pregnancy suggest that other forms of vitamin D may also contribute to the pathophysiology of PET.

Methods: In a cross sectional analysis of normal pregnant women at 1st (n=25) and 3rd trimester (n=21), pregnant women with PET (n=22), and non-pregnant female controls (n=20) vitamin D metabolites were quantified in paired maternal serum, placental, and decidual tissue.

Results: Serum 25(OH)D3 was not significantly different in sera across all four groups. In normal 3rd trimester pregnant women serum active 1,25-dihydroxyvitamin D3 (1,25(OH)$_2$D3) was significantly higher than non-pregnant, normal 1st trimester pregnant, and PET women. Conversely, PET sera showed highest levels of the catabolites 3-epi-25(OH)D3 and 24,25-dihydroxyvitamin D3 (24,25(OH)$_2$D3). Serum albumin was significantly lower in normal 3rd trimester pregnant women and PET relative to normal 1st trimester pregnant women, but there was no change in free/bioavailable 25(OH)D3. In PET placental tissue, 25(OH)D3 and 3-epi-25(OH)D3 were lower than normal 3rd trimester tissue, whilst placental 24,25(OH)$_2$D3 was highest in PET. Tissue 1,25(OH)$_2$D3 was detectable in 1st trimester decidua, which also showed 10-fold higher 25(OH)D3 relative to paired placentae. 3-epi-25(OH)D3 and 24,25(OH)$_2$D3 were not different for decidua and placenta. In normal 3rd trimester pregnant women, total, free and bioavailable maternal 25(OH)D3 correlated with placental 25(OH)D3, but this was not conserved for PET.

Discussion: These data indicate that PET is associated with decreased activation, increased catabolism, and impaired placental uptake of 25(OH)D3.

Introduction

Human pregnancy is associated with important changes in vitamin D physiology. Maternal circulating concentrations of the active form of vitamin D, 1,25-dihydroxyvitamin D3 $(1,25(OH)_2D3)$, increase significantly during early gestation [1]. This appears to be due to increased renal activity of the enzyme 25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase), which converts inactive 25-hydroxyvitamin D $(25(OH)D3)$ to $1,25(OH)_2D3$ [2]. 1α-hydroxylase expression and activity has also been described in human decidua and fetal trophoblast [3-5]. Placental 1α-hydroxylase does not appear to make a major contribution to the elevated maternal $1,25(OH)_2D3$ associated with pregnancy [2]. Instead co-expression of the nuclear vitamin D receptor (VDR) in maternal and fetal placental tissues suggests a more localised role for $1,25(OH)_2D3$. Albeit less well understood, recent studies suggest this extends far beyond the known classical calciotropic effects of vitamin D, and includes key roles in normal decidual immune function and placental implantation [6-9]

Vitamin D-insufficiency is prevalent in pregnant women [10, 11]. Maternal 25(OH)D is the principal determinant of neonatal circulating 25(OH)D3, thus infants of vitamin D–deficient mothers are also at risk of vitamin D-deficiency [12]. Maternal 25(OH)D3-deficiency has also been linked to adverse pregnancy outcomes associated with malplacentation, including preeclampsia (PET), small-for-gestational age and preterm birth [13-17]. Mothers receiving vitamin D supplementation from early pregnancy (two trials, 219 women) have been reported to have a lower risk of PET and a positive association between serum 25(OH)D3 and reduced PET risk has been reported [18]. A recent systematic review and meta-analysis, which included 11 observational studies, found a significant inverse relationship between maternal 25(OH)D3 and risk of PET in 5 of the studies. Meta-analyses similarly suggested an inverse relationship between maternal 25(OH)D3 and PET risk, but could not infer causality due to the insufficient quality of evidence [19, 20].

1

27

28 This heterogeneity of data for vitamin D and PET in part reflects our limited understanding of the

29 effects of vitamin D during pregnancy. Moreover, almost all studies to date have relied on

30 maternal serum concentrations of 25(OH)D3 as the determinant of vitamin D status and

31 function, despite the potential importance of other vitamin D metabolites such as $1,25(OH)_2D3$

32 [21], 3-epi-25(OH)D3 [22], and 24-hydroxylated vitamin D metabolites $(24,25(OH)_2D3)$ [23].

33 Furthermore, placental expression of 1α-hydroxylase suggests that tissue-specific

34 concentrations of 25(OH)D3 and other vitamin D metabolites are likely to be potential

35 determinants of local vitamin D function across gestation [6]. Finally, vitamin D binding protein

36 (DBP) and albumin are known to act as serum transporters of vitamin D metabolites, but also

37 define tissue bioavailability and function by modulating the balance of bound and free forms of

38 vitamin D [24]. The aim of the current study was therefore to characterise the relative impact of

39 each of these facets of vitamin D metabolism and transport on normal and PET pregnancies.

40

41 **Materials and Methods**

42 ***Ethical approval***

43 Written informed consent was obtained from all women recruited into the study. Matched human

44 sera, placenta and decidua samples were collected with the approval of Health Research

45 Authority - West Midlands, Edgbaston Research Ethics Committee (NHS REC 06/Q2707/12

46 [2006 approval]) (RG_14-194 [10.2014 approval]).

47

48 ***Sample collection***

49 All samples were obtained from women in the West Midlands area of the UK (n=88). Patient

50 demographics and baseline clinical data are summarised in **Supplemental Table 1**.

51 Importantly, no significant difference in maternal age or BMI was measured. As anticipated, in

52 the PET group mean arterial blood pressure was significantly raised (p<0.0001) and fetal

53 birthweight reduced (p<0.01) comparative to NP3. There was however no significant difference

54 in gestational age at delivery. 1st trimester sera, placental and decidual samples were obtained

55 from women with uncomplicated pregnancies undergoing surgical termination of pregnancy

56 between 8-13 weeks gestation (n=25), as determined by ultrasound measurement of crown

57 rump length (Walsall Manor NHS Trust).

58

59 Normal uncomplicated 3rd trimester (>37 weeks) (n=21) and PET (>34 weeks) (n=22) sera and

60 placental samples were collected from pregnant women consented prior to delivery at

61 Birmingham Women's Foundation Hospital Trust (BWFHT). All PET cases were prospectively

62 diagnosed according to current International definitions (ISSHP, 2014)[25]; new hypertension

63 presenting after 20 weeks, with one or more of the following new onset conditions: 1. proteinuria

64 (urinary protein: creatinine ratio > 30 mg/mmol or a validated 24-hour urine collection > 300 mg

65 protein); 2. other maternal organ dysfunction (renal insufficiency, liver involvement, neurological

66 and/ or haematological complications); 3. utero-placental dysfunction (fetal growth restriction).

67 PET severity was categorised as; mild - diastolic ≥ 90–99 mmHg, systolic ≥140–149 mmHg

68 (n=9), moderate - diastolic ≥ 100–109 mmHg (n=7), systolic ≥150–159 mmHg, severe - diastolic

69 ≥ 110 mmHg, systolic ≥160 mmHg (n=6). Maternal mean arterial blood pressure (MABP) was

70 significantly elevated comparative to the normal pregnant control group. A healthy non-pregnant

71 female 'control' group (n=20) was also recruited.

72

73 ***Sample preparation for LC-MS/MS Analysis***

74 Placental biopsies (approximately 1g weight) were defrosted on ice and homogenised in 700μl

75 ice-cold PBS using a gentle MACS tissue dissociator (Miltenyi Biotec, Woking, UK,) with M

76 tubes using pre-set programs developed for total RNA or mRNA isolation from fresh or frozen

77 samples. Homogenates were centrifuged at 10,000g for 5 minutes and the clear homogenate

78 was transferred to a separate Eppendorf tube. Total protein content in the homogenate was

79 immediately measured (ThermoFisher, Waltham, MA, USA).

80

81 ***Extraction of serum and tissues samples for LC-MS/MS analysis***

82 Vitamin D metabolites were extracted from donor serum (0.2 mL) or placental tissue

83 homogenates as described previously [26]. Resulting samples were reconstituted in 125 µL

84 water/methanol (50/50%) for LC-MS/MS analysis as previously described [26] using a Waters

85 ACQUITY ultra performance liquid chromatography [uPLC] coupled to a Waters Xevo TQ-S

86 mass spectrometer [Waters, Manchester, UK]). Analysis was carried out in multiple reaction

87 monitoring (MRM) mode, with optimised MRM transitions for each analyte as described

88 previously [26]. External quality control (QC) samples (LGC Standards, Teddington, UK) for

89 25(OH)D3 and 25(OH)D2 were used to assess accuracy and precision within batch runs. QCs

90 across different concentration ranges to determine inter- and intra- day accuracy and precision

91 for each analyte were as described previously [26]. Data analysis was performed with Waters

92 Target Lynx.

93

94 ***Analysis of DBP and albumin and estimation of free vitamin D metabolites***

95 Human vitamin D binding protein (DBP) (R&D Biosystems, Abingdon, UK), and human albumin

96 (Abcam, Cambridge, UK) were measured using ELISA analyses as per manufacturer's

97 instructions. Serum concentrations of free (total minus DBP and albumin-bound) and

98 bioavailable (total minus DBP bound) serum 25(OH)D3 were calculated based on total

99 25(OH)D3 and DBP/albumin values using equations described previously [27].

100

101 ***Statistics***

102 Unless otherwise stated, data are shown as median values with interquartile ranges (IQR). All

103 statistical analyses were carried out using GraphPad PRISM Version 6.07 software (San Diego,

4

104 CA, USA). Normality was assessed using D'Agostino-Pearson omnibus normality test, with

105 Student's t-test (parametric), or Mann-Whitney (non-parametric) test utilised to compare two

106 data sets. Multifactorial data were compared using either one-way ANOVA (parametric) or

107 Kruskal-Wallis test (non-parametric) based on ranks, with Tukey or Dunn's method used for

108 post hoc multiple-comparison procedures.

109

110 **Results**

111 *Dysregulation of serum vitamin D metabolism in PET*

112 Four serum vitamin D metabolites were consistently quantifiable in both pregnant and non-

113 pregnant women; 25(OH)D3, 1,25(OH)$_2$D3, 24,25(OH)$_2$D3, 3-epi-25(OH)D3. In non-pregnant

114 women 25(OH)D3 concentrations (median 33.4, IQR 20.8–44.3 nmol/L), were similar to healthy

115 1st trimester (NP1, 28.8, 20.3–46.9nmol/L) and 3rd trimester (NP3, 45.2, 32.5–59.2nmol/L)

116 pregnancies, as well as women diagnosed with PET (35.3, 17.7–54.7 nmol/L) (**Figure 1A**). By

117 contrast, serum 1,25(OH)$_2$D3 concentrations in non-pregnant women (34.2, 29.3–55.0 pmol/L),

118 were significantly lower than in pregnant women, including NP1 (113.7, 82.7–198.3 pmol/L,

119 p<0.0001), NP3 (254.7, 195.7–310.1 pmol/L, P<0.0001), and PET (171.2, 113.0–236.3 pmol/L,

120 p<0.0001) groups (**Figure 1B**). Consistent with previous studies [28], NP3 levels of

121 1,25(OH)$_2$D3 were more than two-fold higher than NP1 (p<0.0001), and significantly lower

122 concentrations of 1,25(OH)$_2$D3 (p<0.01) were observed in the PET cohort compared to NP3

123 (**Figure 1B**). Linear regression analysis confirmed gestational age was not a significant

124 determinant of any serum vitamin D metabolite (data not shown).

125

126 Serum concentrations of 24,25(OH)$_2$D3 in non-pregnant women (3.3, 1.6–4.7 nmol/L) were

127 higher than NP1 (1.8, 0.8-3.7 nmol/L), but lower than NP3 (7.6, 5.6-10.0 nmol/L, p<0.05) and

128 PET (10.9, 7.3-22.5 nmol/L, p<0.001) (**Figure 1C**). Both NP3 and PET samples showed

129 significantly higher 24,25(OH)$_2$D3 concentrations than NP1 (both p<0.0001). Concentrations of

5

130 3-epi-25(OH)D3 were lowest in non-pregnant women (5.1, 3.9-6.4 nmol/L). Both NP1 (7.6, 6.0-

131 9.2 nmol/L) and NP3 (7.5, 5.9-8.6 nmol/L) had higher levels of 3-epi-25(OH)D3 but this was not

132 significant. Highest 3-epi-25(OH)D3 levels were observed with PET (8.8, 5.9-11.8 nmol/L), with

133 significant differences compared to non-pregnant (p<0.001), NP1 (p<0.05) and NP3 groups

134 (p<0.05) (**Figure 1D**). In non-pregnant women serum 25(OH)D3 was strongly correlated with

135 $1,25(OH)_2D3$ (p=0.013), $24,25(OH)_2D3$ (p<0.0001) and 3-epi-25(OH)D3 (p=0.012), but similar

136 correlations were not consistently observed in pregnancy (**Supplemental Figure 1**).

137

138 ***Serum DBP, albumin and free/bioavailable 25(OH)D3***

139 Data in **Figure 2A** showed a trend towards increased serum DBP in NP1 and NP3 pregnancies

140 relative to non-pregnant women, but there was no significant difference in DBP between NP3

141 and PET. Serum albumin was significantly lower in NP3 and PET pregnancies relative to non-

142 pregnant women (p<0.001 and p<0.05 respectively) and NP1 pregnancies (p<0.001 and p<0.05

143 respectively) (**Figure 2B**). DBP and albumin values, together with total serum 25(OH)D3 levels,

144 were used to calculate bioavailable (**Figure 2C**), and free serum 25(OH)D3 (**Figure 2D**) but

145 these showed no significant change across pregnancy or with PET.

146

147 Ratios of DBP-bound 25(OH)D3 to total 25(OH)D3 were unaffected by pregnancy or PET

148 (**Supplemental Figure 2A**). However, the suppression of serum albumin with pregnancy

149 significantly decreased the ratio of 'bioavailable' 25(OH)D3 (25(OH)D3 bound to albumin but not

150 DBP) to 'total' serum 25(OH)D3 across normal pregnancy and PET (**Supplemental Figure 2B**).

151 In a similar fashion, elevation of DBP levels in pregnant women resulted in decrease ratios of

152 'free' 25(OH)D3 to total 25(OH)D3, with this effect being more pronounced in PET pregnancies

153 (**Supplemental Figure 2C**).

154

155 ***Decreased placental tissue concentrations of 25(OH)D3 in PET pregnancies***

156 In contrast to the placenta, $1,25(OH)_2D3$ was quantifiable in decidual tissue (17.6, 11.0–23.4

157 pmol/mg protein), and this paralleled increased decidual concentrations of 25(OH)D3 (21.0,

158 9.3–60.5 nmol/mg protein) relative to paired NP1 placentae (1.2, 0.7-2.2 nmol/mg protein,

159 p<0.001) **(Figure 3A)**. By contrast no difference in tissue levels of $24,25(OH)_2D3$ were observed

160 between decidua (0.3, 0.2–0.4 nmol/mg) and placenta (0.2, 0.1–0.3 nmol/mg). Similarly,

161 decidual concentrations of 3-epi-25(OH)D3 (0.1, 0.1–0.3 nmol/mg) were not significantly

162 different to NP1 placental 3-epi-25(OH)D3 (0.2, 0.1–0.3 nmol/mg) (**Figure 3A**).

163

164 In placenta tissue, concentrations of 25(OH)D3 increased significantly from NP1 (1.2, 0.7-2.2

165 nmol/mg protein) to NP3 (5.0, 4.0-6.5 nmol/mg protein, p<0.0001), but this effect was not

166 observed for PET placenta levels of 25(OH)D3 (2.5, 1.4-3.5 nmol/mg protein) which were

167 significantly lower than NP3 values (p<0.01) **(Figure 3B)**. Consistent with maternal serum data,

168 placental $24,25(OH)_2D3$ values were highest for PET (0.4, 0.3–0.6 nmol/ mg) relative to NP3

169 (0.3, 0.3–0.5 nmol/mg) and NP1 (0.2, 0.1-0.4 nmol/mg, p<0.01) (**Figure 3B**). Placental 3-epi-

170 25OHD3 values were also higher for PET (0.4, 0.3–0.7 nmol/mg) relative to both NP3 (0.3, 0.2–

171 0.4 nmol/mg, p<0.05) and NP1 pregnancies (0.2, 0.1–0.3 nmol/mg, p<0.001) (**Figure 3B**).

172 Placental concentrations of $1,25(OH)_2D3$ were below the lower limit of quantification. In NP1

173 (data not shown) and NP3 pregnancies (**Figure 4A**) placental concentrations of 25(OH)D3

174 correlated with maternal serum total, DBP-bound, bioavailable and free 25(OH)D3. By contrast,

175 placental concentrations of 25(OH)D3 in PET pregnancies showed no association with any form

176 of maternal serum 25(OH)D3 (**Figure 4B**).

177

178 **Discussion**

179 PET is a pregnancy-specific hypertensive, multisystem syndrome which complicates up to 8%

180 of pregnancies [25], and is associated with significantly increased maternal and perinatal

181 mortality and morbidity [29]. Although pathogenesis is not fully understood, PET is characterised

7

182   by abnormal decidual maternal spiral artery remodelling by invading fetal extravillous

183   trophoblast (EVT) cells. [30]. Importantly, this critical placentation process appears sensitive to

184   local vitamin D metabolites within both decidua and placental tissues [9]. In contrast to previous

185   reports describing decreased serum 25(OH)D3 in PET [13, 14, 31], vitamin D-deficiency was

186   observed for most of the women in the current study, despite this being a predominantly white

187   Caucasian cohort. This may be due to the smaller size and non-matched cohort used [14], or

188   the fact that some studies quantified serum 25(OH)D3 using ELISA technology which cannot

189   distinguish between 25(OH)D3 and 3-epi-25(OH)D3 and may therefore over-estimate serum

190   vitamin D 'status' [13, 31]. Nevertheless, the over-arching conclusion from data presented here

191   is that simple measurement of serum 25(OH)D3 provides a very limited perspective of vitamin D

192   in pregnancy.

193

194   Previous studies have reported PET-associated declines in serum $1,25(OH)_2D3$ [31, 32], similar

195   to those reported in the current study. This may be due to decreased serum levels of insulin-like

196   growth factor 1 [32], a stimulator of renal 1α-hydroxylase, or lower expression of 1α-hydroxylase

197   in the placenta [33], but other PET studies have reported increased whole human placental

198   tissue 1α-hydroxylase expression [34]. Data presented here suggest that metabolism of

199   25(OH)D3 to $24,25(OH)_2D3$ may indirectly lower $1,25(OH)_2D3$ in PET. Enhanced 'catabolism' of

200   25(OH)D3 to $24,25(OH)_2D3$ in PET may be due to increased placental (trophoblast) expression

201   of the enzyme 24-hydroxylase [34], although the underlying basis for this remains unclear [35].

202   Alternative metabolism of vitamin D may also occur via epimerisation of 25(OH)D3. The

203   resulting 3-epi-25(OH)D3 can be converted to $3-epi-1,25(OH)_2D3$, and then bind to VDR to

204   activate target gene transcription [36]. However, $3-epi-1,25(OH)_2D3$ is a much less potent VDR

205   agonist than $1,25(OH)_2D3$, suggesting that epimerisation of 25(OH)D3 acts to dial-down VDR

206   activity by generating a less effective ligand for the receptor [37]. It is notable that 3-epi-

8

207 25(OH)D3 concentrations were significantly higher in the PET cohort, so this metabolic pathway

208 may also play a key role in the dysregulation of vitamin D function in PET.

209

210 This is the first study to use paired placental, decidual and serum samples to assess the

211 relationship between circulating and tissue-specific levels of vitamin D metabolites. The

212 relatively high levels of 25(OH)D3 in decidua enabled quantification of $1,25(OH)_2D3$, but

213 determinants of both decidual 25(OH)D3 and $1,25(OH)_2D3$ remain unclear (**Supplemental**

214 **Figure 2**). The most likely determinant of decidual $1,25(OH)_2D3$ is local tissue expression of 1α-

215 hydroxylase. In unpublished studies we have shown that decidual 1α-hydroxylase mRNA

216 correlates with mRNA for inflammatory cytokines such as interleukin-6 and interferon-γ,

217 suggesting that immune activity could be a key driver of decidual $1,25(OH)_2D3$. Less clear is

218 what determines decidual levels of the substrate for 1α-hydroxylase, 25(OH)D3. It was

219 interesting that neither maternal nor placental 25(OH)D3 showed any correlation with decidual

220 25(OH)D3, despite the proximity of these tissues (**Supplemental Figure 2**), suggesting that the

221 the decidua has an autonomously regulated vitamin D system.

222

223 In contrast to the decidua, data for placental tissue support the general assumption that

224 variations in circulating 25(OH)D3 are manifested by equivalent tissue changes in 25(OH)D3. In

225 NP3, placental 25(OH)D3 was closely correlated with maternal 25(OH)D well beyond levels of

226 sufficiency (>75 nmoL/L). This was not observed in placentas from PET pregnancies,

227 irrespective of serum 25(OH)D3 concentration (**Figure 4B**). This may, in part, reflect

228 dysregulation of tissue catabolism of 25(OH)D3, as placental $24,25(OH)_2D3$ was highest for

229 PET. However, tissue 3-epi-25(OH)D3 was significantly lower in PET placentas, suggesting that

230 this catabolic pathway does not contribute to suppression of 25(OH)D3 in the placenta.

231

232 In recent years there has been increasing interest in the potential role of serum DBP not only as

233 a transporter of vitamin D metabolites, but also as a determinant of 25(OH)D3 tissue access

234 either as unbound or 'free' 25(OH)D3, or through receptor-mediated uptake of DBP-bound

235 25(OH)D3 [24]. In the current study variations in serum DBP and albumin across pregnancy

236 (**Figure 2**) resulted in subtle changes in the relative proportions of bioavailable and free

237 25(OH)D3 (**Supplemental Figure 3**). It has been recognised for many years that serum

238 albumin decreases with pregnancy, due to increased maternal blood volume [38]. This may be

239 exacerbated in PET, although the extent to which this occurs varies with disease severity [38].

240 Previous studies using 1st trimester serum did not demonstrate any significant variation in DBP

241 or 25(OH)D3 between pregnancies that went on to normal term or PET delivery [39].

242 For both NP1 and NP3, serum DBP correlated with placental DBP, but this was not observed in

243 PET placentas, or NP1 decidua (**Supplemental Figure 4A**). PET may therefore involve

244 dysregulated endocytic uptake of DBP via the membrane receptor megalin which is expressed

245 in the placenta [40]. Although DBP uptake by the placenta appears to be dysregulated in PET,

246 other data do not support a major role for DBP as a determinant of placental or decidual

247 25(OH)D3. Firstly, placental DBP was higher in NP1 than NP3, whereas placental 25(OH)D3

248 was higher in NP3 (**Supplemental Figure 4A**). Most importantly there was no correlation

249 between placental or decidual DBP and the levels of 25(OH)D3 in these tissues for NP1

250 (**Supplemental Figure 4C** and **4D**) or NP3 (data not shown). Collectively these data suggest

251 that the close association between maternal serum 25(OH)D3 and levels of this metabolite in

252 placental tissue involves placental uptake of DBP, but other mechanisms determine the final

253 tissue-specific concentrations of 25(OH)D3. Dysregulation of this process in PET may reflect

254 aberrant spiral artery development and placental blood flow, both of which are associated with

255 malplacentation and may alter DBP uptake and 25(OH)D3 metabolism. We have shown

256 previously that 25(OH)D3 and 1,25(OH)$_2$D3 promote matrix invasion by human trophoblastic

257 cells [9], and similarly demonstrated dysregulated placental vascularisation and elevated blood

258 pressure in vitamin D-deficient pregnant mice [41]. Thus further studies are required to

259 determine whether decreased placental 25(OH)D3 is a cause or consequence of PET.

260 The validity of the monoclonal antibody to DBP used in the R&D assay employed in the current

261 study has been subject to recent debate, specifically reported differential immunoreactivity

262 against epitopes on major DBP isoforms [42, 43]. This potential limitation of the DBP assay is

263 specifically relevant to black populations, and it is important to recognise that the cohort in the

264 current study was predominantly white. Nevertheless, future studies will benefit from direct

265 measurement method for 'free' 25(OH)D3 and using newly established assays [44].

266

267 The over-arching conclusions from this study are: 1) that PET is characterised by changes in

268 multiple vitamin D metabolic pathways, emphasising the limited information to be gained from

269 measurement of maternal 25(OH)D3; 2) changes in maternal DBP and albumin do not appear

270 to have a major impact on the bioavailability and placental/decidual accumulation of vitamin D;

271 3) in normal healthy pregnancies, maternal serum 25(OH)D3 is closely correlated with placental

272 25(OH)D3, underlining the potential benefits of vitamin D supplementation in pregnancy; 4) this

273 effect is lost in PET pregnancies, and the potential impact of this on resulting offspring will be a

274 target for future studies; 5) in contrast to the placenta, the decidua can synthesise detectable

275 levels of $1,25(OH)_2D3$. However, the underlying mechanistic basis for regulation of this

276 metabolism in the decidua is still unclear, and requires further investigation. An important

277 limitation of the present study is the large inter-group variability in all vitamin D metabolites

278 measured and most likely reflects the small sample size and non-matched study design.

279 Validation of these findings in a high-powered, matched cohort study including pregnant women

280 with PET versus normotensive pregnant and non-pregnant controls is required to inform any

281 future vitamin D supplementation trial targeting correction of the vitamin D metabolome.

282

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

References

[1] R. Kumar, W.R. Cohen, P. Silva, F.H. Epstein, Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation, The Journal of clinical investigation 63(2) (1979) 342-4.

[2] M. Turner, P.E. Barre, A. Benjamin, D. Goltzman, M. Gascon-Barre, Does the maternal kidney contribute to the increased circulating 1,25-dihydroxyvitamin D concentrations during pregnancy?, Mineral and electrolyte metabolism 14(4) (1988) 246-52.

[3] T.K. Gray, G.E. Lester, R.S. Lorenc, Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy, Science 204(4399) (1979) 1311-3.

[4] Y. Weisman, A. Harell, S. Edelstein, M. David, Z. Spirer, A. Golander, 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta, Nature 281(5729) (1979) 317-9.

[5] D. Zehnder, K.N. Evans, M.D. Kilby, J.N. Bulmer, B.A. Innes, P.M. Stewart, M. Hewison, The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua, The American journal of pathology 161(1) (2002) 105-14.

[6] N.Q. Liu, M. Hewison, Vitamin D, the placenta and pregnancy, Arch Biochem Biophys 523(1) (2012) 37-47.

[7] N.Q. Liu, A.T. Kaplan, V. Lagishetty, Y.B. Ouyang, Y. Ouyang, C.F. Simmons, O. Equils, M. Hewison, Vitamin D and the regulation of placental inflammation, J Immunol 186(10) (2011) 5968-74.

[8] J. Tamblyn, M. Hewison, C. Wagner, J. Bulmer, M. Kilby, Immunological role of vitamin D at the maternal–fetal interface, Journal of Endocrinology 224(3) (2015) R107-R121.

[9] S.Y. Chan, R. Susarla, D. Canovas, E. Vasilopoulou, O. Ohizua, C.J. McCabe, M. Hewison, M.D. Kilby, Vitamin D promotes human extravillous trophoblast invasion in vitro, Placenta 36(4) (2015) 403-9.

[10] M.K. Javaid, S.R. Crozier, N.C. Harvey, C.R. Gale, E.M. Dennison, B.J. Boucher, N.K. Arden, K.M. Godfrey, C. Cooper, Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study, Lancet 367(9504) (2006) 36-43.

[11] L.M. Bodnar, H.N. Simhan, R.W. Powers, M.P. Frank, E. Cooperstein, J.M. Roberts, High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates, The Journal of nutrition 137(2) (2007) 447-52.

[12] S.N. Karras, I. Shah, A. Petroczi, D.G. Goulis, H. Bili, F. Papadopoulou, V. Harizopoulou, B.C. Tarlatzis, D.P. Naughton, An observational study reveals that neonatal vitamin D is primarily determined by maternal contributions: implications of a new assay on the roles of vitamin D forms, Nutr J 12 (2013) 77.

[13] L.M. Bodnar, J.M. Catov, H.N. Simhan, M.F. Holick, R.W. Powers, J.M. Roberts, Maternal vitamin D deficiency increases the risk of preeclampsia, J Clin Endocrinol Metab 92(9) (2007) 3517-22.

[14] M. Djekic-Ivankovic, H. Weiler, G. Jones, M. Kaufmann, J. Kaludjerovic, V. Aleksic-Velickovic, L.M. Mandic, M. Glibetic, Vitamin D status in mothers with pre-eclampsia and their infants: a case-control study from Serbia, a country without a vitamin D fortification policy, Public Health Nutr (2016) 1-11.

[15] H.H. Burris, S.L. Rifas-Shiman, K. Kleinman, A.A. Litonjua, S.Y. Huh, J.W. Rich-Edwards, C.A. Camargo, Jr., M.W. Gillman, Vitamin D deficiency in pregnancy and gestational diabetes mellitus, American journal of obstetrics and gynecology 207(3) (2012) 182 e1-8.

[16] L.M. Bodnar, J.M. Catov, J.M. Zmuda, M.E. Cooper, M.S. Parrott, J.M. Roberts, M.L. Marazita, H.N. Simhan, Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women, J Nutr 140(5) 999-1006.

[17] C.L. Wagner, C. Baggerly, S. McDonnell, K.A. Baggerly, C.B. French, L. Baggerly, S.A. Hamilton, B.W. Hollis, Post-hoc analysis of vitamin D status and reduced risk of preterm birth in two vitamin D pregnancy cohorts compared with South Carolina March of Dimes 2009-2011 rates, The Journal of steroid biochemistry and molecular biology 155(Pt B) (2016) 245-51.

[18] L.M. De-Regil, C. Palacios, L.K. Lombardo, J.P. Pena-Rosas, Vitamin D supplementation for women during pregnancy, Cochrane Database Syst Rev 1 (2016) CD008873.

[19] E. Hypponen, A. Cavadino, D. Williams, A. Fraser, A. Vereczkey, W.D. Fraser, F. Banhidy, D. Lawlor, A.E. Czeizel, Vitamin D and pre-eclampsia: original data, systematic review and meta-analysis, Ann Nutr Metab 63(4) (2013) 331-40.

[20] N.C. Harvey, C. Holroyd, G. Ntani, K. Javaid, P. Cooper, R. Moon, Z. Cole, T. Tinati, K. Godfrey, E. Dennison, N.J. Bishop, J. Baird, C. Cooper, Vitamin D supplementation in pregnancy: a systematic review, Health technology assessment 18(45) (2014) 1-190.

[21] C. Thota, R. Menon, S.J. Fortunato, L. Brou, J.E. Lee, A. Al-Hendy, 1,25-Dihydroxyvitamin D deficiency is associated with preterm birth in African American and Caucasian women, Reprod Sci 21(2) (2014) 244-50.

[22] S.E. Bennett, C. Casey, J. McPeake, D.R. McCance, J.G. Manderson, A. McGinty, 3-Epi-25 hydroxyvitamin D in pregnancy, Pregnancy Hypertens 4(3) (2014) 236.

[23] A.D. Shah, E.C. Hsiao, B. O'Donnell, K. Salmeen, R. Nussbaum, M. Krebs, S. Baumgartner-Parzer, M. Kaufmann, G. Jones, D.D. Bikle, Y. Wang, A.S. Mathew, D. Shoback, I. Block-Kurbisch, Maternal Hypercalcemia Due to Failure of 1,25-Dihydroxyvitamin-D3 Catabolism in a Patient With CYP24A1 Mutations, The Journal of clinical endocrinology and metabolism 100(8) (2015) 2832-6.

[24] R.F. Chun, B.E. Peercy, E.S. Orwoll, C.M. Nielson, J.S. Adams, M. Hewison, Vitamin D and DBP: the free hormone hypothesis revisited, The Journal of steroid biochemistry and molecular biology 144 Pt A (2014) 132-7.

[25] A.L. Tranquilli, M.A. Brown, G.G. Zeeman, G. Dekker, B.M. Sibai, The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP), Pregnancy Hypertens 3(1) (2013) 44-7.

[26] C. Jenkinson, A.E. Taylor, Z.K. Hassan-Smith, J.S. Adams, P.M. Stewart, M. Hewison, B.G. Keevil, High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum, J Chromatogr B Analyt Technol Biomed Life Sci 1014 (2016) 56-63.

[27] R.F. Chun, B.E. Peercy, J.S. Adams, M. Hewison, Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling, PloS one 7(1) (2012) e30773.

[28] S.N. Karras, P. Anagnostis, E. Bili, D. Naughton, A. Petroczi, F. Papadopoulou, D.G. Goulis, Maternal vitamin D status in pregnancy and offspring bone development: the unmet needs of vitamin D era, Osteoporos Int 25(3) (2014) 795-805.

[29] B.W. Mol, C.T. Roberts, S. Thangaratinam, L.A. Magee, C.J. de Groot, G.J. Hofmeyr, Pre-eclampsia, Lancet 387(10022) (2016) 999-1011.

[30] S.J. Fisher, Why is placentation abnormal in preeclampsia?, American journal of obstetrics and gynecology 213(4 Suppl) (2015) S115-22.

[31] C. Lechtermann, B.P. Hauffa, R. Herrmann, M.M. Schundeln, A. Gellhaus, M. Schmidt, C. Grasemann, Maternal vitamin D status in preeclampsia: seasonal changes are not influenced by placental gene expression of vitamin D metabolizing enzymes, PloS one 9(8) (2014) e105558.

[32] A. Halhali, L. Diaz, E. Avila, A.C. Ariza, M. Garabedian, F. Larrea, Decreased fractional urinary calcium excretion and serum 1,25-dihydroxyvitamin D and IGF-I levels in preeclampsia, The Journal of steroid biochemistry and molecular biology 103(3-5) (2007) 803-6.

[33] L. Diaz, C. Arranz, E. Avila, A. Halhali, F. Vilchis, F. Larrea, Expression and activity of 25-hydroxyvitamin D-1 alpha-hydroxylase are restricted in cultures of human syncytiotrophoblast cells from preeclamptic pregnancies, The Journal of clinical endocrinology and metabolism 87(8) (2002) 3876-82.

[34] R. Ma, Y. Gu, S. Zhao, J. Sun, L.J. Groome, Y. Wang, Expressions of vitamin D metabolic components VDBP, CYP2R1, CYP27B1, CYP24A1, and VDR in placentas from normal and preeclamptic pregnancies, American journal of physiology. Endocrinology and metabolism 303(7) (2012) E928-35.

14

402 [35] D. Fischer, A. Schroer, D. Ludders, T. Cordes, B. Bucker, J. Reichrath, M. Friedrich, Metabolism of
403 vitamin D3 in the placental tissue of normal and preeclampsia complicated pregnancies and premature
404 births, Clin Exp Obstet Gynecol 34(2) (2007) 80-4.
405 [36] S. Messerlian, X. Gao, R. St-Arnaud, The 3-epi- and 24-oxo-derivatives of 1alpha,25
406 dihydroxyvitamin D(3) stimulate transcription through the vitamin D receptor, J Steroid Biochem Mol
407 Biol 72(1-2) (2000) 29-34.
408 [37] J.C. Fleet, J. Bradley, G.S. Reddy, R. Ray, R.J. Wood, 1 alpha,25-(OH)2-vitamin D3 analogs with
409 minimal in vivo calcemic activity can stimulate significant transepithelial calcium transport and mRNA
410 expression in vitro, Archives of biochemistry and biophysics 329(2) (1996) 228-34.
411 [38] C.H. Horne, P.W. Howie, R.B. Goudie, Serum-alpha2-macroglobulin, transferrin, albumin, and IgG
412 levels in preeclampsia, Journal of clinical pathology 23(6) (1970) 514-6.
413 [39] C.E. Powe, E.W. Seely, S. Rana, I. Bhan, J. Ecker, S.A. Karumanchi, R. Thadhani, First trimester
414 vitamin D, vitamin D binding protein, and subsequent preeclampsia, Hypertension 56(4) (2010) 758-63.
415 [40] S. Lundgren, T. Carling, G. Hjalm, C. Juhlin, J. Rastad, U. Pihlgren, L. Rask, G. Akerstrom, P. Hellman,
416 Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein, J Histochem Cytochem
417 45(3) (1997) 383-92.
418 [41] N.Q. Liu, Y. Ouyang, Y. Bulut, V. Lagishetty, S.Y. Chan, B.W. Hollis, C. Wagner, O. Equils, M. Hewison,
419 Dietary vitamin D restriction in pregnant female mice is associated with maternal hypertension and
420 altered placental and fetal development, Endocrinology 154(7) (2013) 2270-80.
421 [42] C.E. Powe, M.K. Evans, J. Wenger, A.B. Zonderman, A.H. Berg, M. Nalls, H. Tamez, D. Zhang, I. Bhan,
422 S.A. Karumanchi, N.R. Powe, R. Thadhani, Vitamin D-binding protein and vitamin D status of black
423 Americans and white Americans, N Engl J Med 369(21) (2013) 1991-2000.
424 [43] C.M. Nielson, K.S. Jones, R.F. Chun, J.M. Jacobs, Y. Wang, M. Hewison, J.S. Adams, C.M. Swanson,
425 C.G. Lee, D. Vanderschueren, S. Pauwels, A. Prentice, R.D. Smith, T. Shi, Y. Gao, A.A. Schepmoes, J.M.
426 Zmuda, J. Lapidus, J.A. Cauley, R. Bouillon, I. Schoenmakers, E.S. Orwoll, Free 25-Hydroxyvitamin D:
427 Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations, The Journal of clinical
428 endocrinology and metabolism 101(5) (2016) 2226-34.
429 [44] C.M. Nielson, K.S. Jones, R.F. Chun, J.M. Jacobs, Y. Wang, M. Hewison, J.S. Adams, C.M. Swanson,
430 C.G. Lee, D. Vanderschueren, S. Pauwels, A. Prentice, R.D. Smith, T. Shi, Y. Gao, A.A. Schepmoes, J.M.
431 Zmuda, J. Lapidus, J.A. Cauley, R. Bouillon, I. Schoenmakers, E.S. Orwoll, G. Osteoporotic Fractures in
432 Men Research, Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-
433 Genotypic Associations, The Journal of clinical endocrinology and metabolism 101(5) (2016) 2226-34.

434

435

436

437

438

439

440

A.

B.

C.

D.

A.

B.

A. NP3

B. PET

R=0.638
P=0.004

R=0.071
P=0.786

Placenta 25OHD3 (nmol/mg protein)
Total serum 25OHD3 (nmol/L)

R=0.632
P=0.005

R=0.114
P=0.662

Placenta 25OHD3 (nmol/mg protein)
DBP-bound serum 25OHD3 (nmol/L)

R=0.457
P=0.056

R=0.248
P=0.337

Placenta 25OHD3 (nmol/mg protein)
Bioavailable serum 25OHD3 (nmol/L)

R=0.567
P=0.014

R=0.213
P=0.412

Placenta 25OHD3 (nmol/mg protein)
Free serum 25OHD3 (nmol/L)

1 **Legends to figures**

2 **Figure 1. Serum vitamin D metabolites in pregnant and non-pregnant women.** Serum

3 concentrations of: A) 25-hydroxyvitamin D3 (25(OH)D3) nmol/L; B) 1,25-dihydroxyvitamin D3

4 (1,25(OH)$_2$D3) pmol/L; C) 24,25-dihydroxyvitamin D3 (24,25(OH)$_2$D3) nmol/L; D) 3-epi-

5 25(OH)D3 nmol/L. Samples groups were: non-pregnant women; healthy 1st trimester (NP1);

6 healthy 3rd trimester (NP3); preeclampsia 3rd trimester (PET). Statistically significant variations

7 are indicated, * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$.

8

9 **Figure 2. DBP, albumin and 25(OH)D3 bioavailability in pregnant and non-pregnant**

10 **women.** Serum concentrations of: A) vitamin D binding protein (DBP) (μmol/L); B) albumin

11 (μmol/L); C) DBP-bound 25-hydroxyvitamin D3 (25(OH)D3) (nmol/L); D) bioavailable 25(OH)D3;

12 E) free 25(OH)D3. Samples groups were: non-pregnant women; healthy 1st trimester (NP1);

13 healthy 3rd trimester (NP3); preeclampsia 3rd trimester (PET). Statistically significant variations

14 are indicated, * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p< 0.0001$.

15

16 **Figure 3. Placental and decidual tissue vitamin D metabolites in pregnant women.**

17 A) Comparison of decidual and placental concentrations of 1,25-dihydroxyvitamin D3

18 (1,25(OH)D3), 25-hydroxyvitamijn D3 (25(OH)D3), 24,25-dihydroxyvitamin D3 (24,25(OH)$_2$D3),

19 and 3-epi-25(OH)D3 in NP1 pregnancies. All nmol/mg decidual protein. B) Placental

20 concentrations of 25(OH)D3, 24,25(OH)$_2$D3, and 3-epi-25(OH)D3 in: healthy 1st trimester (NP1);

21 healthy 3rd trimester (NP3); pre-eclampsia 3rd trimester (PET) pregnancies. All nmol/mg

22 placental protein. Statistically significant variations are indicated, * $p<0.05$, ** $p<0.01$, ***

23 $p<0.001$, **** $p<0.0001$.

24

25 **Figure 4. Effect of maternal serum 25-hydroyxvitamin D3 (25(OH)D3) on placental**

26 **concentrations of 25(OH)D3.** Serum concentrations of total, DBP-bound, bioavailable and free

27   25-hydroxyvitamin D3 (25(OH)D3) (nmol/L) were correlated with placental tissue concentrations

28   of 25(OH)D3 (nmol/g placental tissue) in healthy 1st trimester (NP1), healthy 3rd trimester (NP3)

29   and pre-eclampsia 3rd trimester (PET) samples.

30

31

32

● Activation of vitamin D is decreased and its catabolism increased in preeclampsia

● Maternal and placental vitamin D are correlated but this does not occur with decidua

● Placental accumulation of vitamin D is impaired in preeclampsia

● Placental uptake of vitamin D binding protein is dysregulated in preeclampsia